MX2021001606A - Tratamiento de la malignidades de las celulas b. - Google Patents
Tratamiento de la malignidades de las celulas b.Info
- Publication number
- MX2021001606A MX2021001606A MX2021001606A MX2021001606A MX2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A MX 2021001606 A MX2021001606 A MX 2021001606A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- cell malignancies
- pi3k
- inhibitor
- administered
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000036210 malignancy Effects 0.000 title 1
- 239000012828 PI3K inhibitor Substances 0.000 abstract 2
- 108091007960 PI3Ks Proteins 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 201000003444 follicular lymphoma Diseases 0.000 abstract 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718929P | 2018-08-14 | 2018-08-14 | |
| US201862775797P | 2018-12-05 | 2018-12-05 | |
| US201962836511P | 2019-04-19 | 2019-04-19 | |
| PCT/US2019/046411 WO2020036999A1 (en) | 2018-08-14 | 2019-08-13 | Treatment of b cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021001606A true MX2021001606A (es) | 2021-04-19 |
Family
ID=69525845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001606A MX2021001606A (es) | 2018-08-14 | 2019-08-13 | Tratamiento de la malignidades de las celulas b. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210299134A1 (https=) |
| EP (1) | EP3836935A4 (https=) |
| JP (1) | JP2021534115A (https=) |
| KR (1) | KR20210043635A (https=) |
| CN (1) | CN112888441A (https=) |
| AU (1) | AU2019321432A1 (https=) |
| BR (1) | BR112021002760A2 (https=) |
| CA (1) | CA3109184A1 (https=) |
| IL (1) | IL280726A (https=) |
| MA (1) | MA53236A (https=) |
| MX (1) | MX2021001606A (https=) |
| SG (1) | SG11202101450VA (https=) |
| TW (1) | TW202021591A (https=) |
| WO (1) | WO2020036999A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI572599B (zh) | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| US11304953B2 (en) | 2017-05-23 | 2022-04-19 | Mei Pharma, Inc. | Combination therapy |
| KR20200041358A (ko) | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011338530B2 (en) * | 2010-12-06 | 2017-06-15 | Follica, Inc. | Methods for treating baldness and promoting hair growth |
| TWI572599B (zh) * | 2011-03-28 | 2017-03-01 | Ｍｅｉ製藥公司 | （α－經取代之芳烷胺基及雜芳烷胺基）嘧啶基及１，３，５－三基苯并咪唑，其醫藥組合物及其在治療增生性疾病之用途 |
| HUE049175T2 (hu) * | 2014-09-23 | 2020-09-28 | Hoffmann La Roche | Eljárás anti-CD79b immunkonjugátumok alkalmazására |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| KR20180042356A (ko) * | 2015-08-24 | 2018-04-25 | 에피자임, 인코포레이티드 | 암 치료 방법 |
| EP3487878A4 (en) * | 2016-07-20 | 2020-03-25 | University of Utah Research Foundation | CD229-CAR-T CELLS AND METHOD FOR USE THEREOF |
| IL292938A (en) * | 2016-09-19 | 2022-07-01 | Mei Pharma Inc | Combined treatment |
| WO2018060833A1 (en) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| WO2018082444A1 (zh) * | 2016-11-02 | 2018-05-11 | 叶宝欢 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| KR20200041358A (ko) * | 2017-08-14 | 2020-04-21 | 메이 파마, 아이엔씨. | 병용 요법 |
-
2019
- 2019-08-13 SG SG11202101450VA patent/SG11202101450VA/en unknown
- 2019-08-13 EP EP19849451.0A patent/EP3836935A4/en not_active Withdrawn
- 2019-08-13 AU AU2019321432A patent/AU2019321432A1/en not_active Abandoned
- 2019-08-13 MA MA053236A patent/MA53236A/fr unknown
- 2019-08-13 MX MX2021001606A patent/MX2021001606A/es unknown
- 2019-08-13 CA CA3109184A patent/CA3109184A1/en active Pending
- 2019-08-13 WO PCT/US2019/046411 patent/WO2020036999A1/en not_active Ceased
- 2019-08-13 CN CN201980067607.2A patent/CN112888441A/zh active Pending
- 2019-08-13 KR KR1020217007417A patent/KR20210043635A/ko not_active Ceased
- 2019-08-13 BR BR112021002760-2A patent/BR112021002760A2/pt not_active IP Right Cessation
- 2019-08-13 US US17/268,052 patent/US20210299134A1/en not_active Abandoned
- 2019-08-13 JP JP2021506716A patent/JP2021534115A/ja active Pending
- 2019-08-14 TW TW108128967A patent/TW202021591A/zh unknown
-
2021
- 2021-02-08 IL IL280726A patent/IL280726A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112888441A (zh) | 2021-06-01 |
| WO2020036999A1 (en) | 2020-02-20 |
| TW202021591A (zh) | 2020-06-16 |
| KR20210043635A (ko) | 2021-04-21 |
| EP3836935A1 (en) | 2021-06-23 |
| CA3109184A1 (en) | 2020-02-20 |
| MA53236A (fr) | 2021-06-23 |
| EP3836935A4 (en) | 2022-09-14 |
| IL280726A (en) | 2021-03-25 |
| SG11202101450VA (en) | 2021-03-30 |
| BR112021002760A2 (pt) | 2021-05-11 |
| JP2021534115A (ja) | 2021-12-09 |
| AU2019321432A1 (en) | 2021-03-25 |
| US20210299134A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
| MX2021000847A (es) | Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077. | |
| MX2022014104A (es) | Inhibidores de atr para el tratamiento del cancer. | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| ZA202107579B (en) | Pharmaceutical combinations for the treatment of cancer | |
| MX2020009773A (es) | Terapia de combinacion. | |
| MX2020008906A (es) | Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. | |
| MX2022005123A (es) | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. | |
| EP4349412A3 (en) | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer | |
| NZ628320A (en) | Treatment of psoriatic arthritis using apremilast | |
| MX2020001727A (es) | Terapia de combinacion. | |
| MX379621B (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer | |
| NZ760459A (en) | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| MX2019002925A (es) | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. | |
| MX2019013862A (es) | Terapia de combinacion. | |
| MX2021001606A (es) | Tratamiento de la malignidades de las celulas b. | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| MX2020003954A (es) | Vectores lentivirales para suministro de pklr para el tratamiento de deficiencia de piruvato quinasa. | |
| MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
| MX390121B (es) | Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas. | |
| MX2016015161A (es) | Metodos de tratamiento de cancer de mama luminal a positivo para pr con inhibidor de pi3k, pictilisib. | |
| MX2023002104A (es) | Composiciones y métodos para tratar cánceres positivos para egfr. | |
| MX2019008233A (es) | Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. |